Results 151 to 160 of about 2,722,809 (208)

Drug Exposure Dictates Evolutionary Dynamics of Drug-Resistant Tuberculosis: A Longitudinal Cohort Study in Beijing, China. [PDF]

Infect Drug Resist
Wen S, Li H, Shi Y, Wei R, Ge F, Pang Y, Liu Y.   +6 more
europepmc   +1 more source

Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis. [PDF]

BMJ Glob Health
Moon S, Vieira MCF, Large K.
europepmc   +1 more source

Lineages of Mycobacterium tuberculosis complex associated with pulmonary drug-resistant tuberculosis in Africa: a systematic review. [PDF]

BMJ Public Health
Gweba C, Oyefabi AO, Awopeju A, Jabaka RD, Uzairue LI.   +4 more
europepmc   +1 more source

Routine Molecular Surveillance of Drug-Resistant Tuberculosis: Translating Mutation Proxies into Clinical Governance Intelligence in Rural Eastern Cape. [PDF]

Healthcare (Basel)
Sonka B, Hosu MC, Dlatu N, Makola TV, Faye LM.   +4 more
europepmc   +1 more source

Factors Influencing Early Sputum Culture Conversion in Pulmonary Drug-resistant Tuberculosis. [PDF]

J Glob Infect Dis
Kotokey UK, Kumari S.
europepmc   +1 more source

Dietary Intake Analyses for the Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis (PandrTB) Pharmacokinetic Sub-Study of the endTB and endTB-Q Clinical Trials

Hans L, Swart R, Velásquez GE, Mitnick CD, Guglielmetti L, Velarde FG, Arshad MS, Magzumova A, Stambekova A, Mohale S, Nguyen HT, Varaine F, McIlleron H.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Management of drug-resistant tuberculosis

Lancet, The, 2019
Drug-resistant tuberculosis is a major public health concern in many countries. Over the past decade, the number of patients infected with Mycobacterium tuberculosis resistant to the most effective drugs against tuberculosis (ie, rifampicin and isoniazid), which is called multidrug-resistant tuberculosis, has continued to increase.
Dumitru Chesov, C Horsburgh, Keertan Dheda   +2 more
exaly   +3 more sources